london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Converting resistant neovascular age related macular degeneration to aflibercept

Poster Details

First Author: T.Georgouli UK

Co Author(s):    D. Burton   S. Mackenzie   G. Walters            0   0 0   0 0   0 0   0 0

Abstract Details


Patients with neovascular age related macular degeneration are often treated with multiple ranibizumab injections without resolution of fluid. The purpose of this study was to evaluate the short term outcomes of aflibercept intravitreal injection on neovascular age related macular degeneration previously treated with multiple ranibizumab injections.


Ophthalmology Department, Harrogate District Hospital, UK


50 consecutive patients (52 eyes) with neovascular age related macular degeneration were prospectively included in the study. All cases were resistant to multiple ranibizumab injections and were converted aflibercept. Injection history, visual acuity, OCT central subfield thickness (CST) and central foveal thickness(CFT) blindly evaluated by two assessors before ranibizumab, and before aflibercept and at 1 month follow -up after one aflibercept injection were studied.


The patients received an average of 22 injections of ranibizumab prior to aflibercept. No difference in the visual acuities was noted with either treatment. Ranibizumab resulted in a statistically significant decrease in the CST and FT by 22% and 33% respectively. A single aflibercept injection further decreased the CST by 12% (p<0.005) and FT by 24% (p<0.001). A strong correlation between the CST and FT was noted. No correlation of improvement in CST and FT with the VA or prior numbers of ranibizumab injections was found.


These data support the idea that aflibercept intravitreal injections could be beneficial in restoring normal anatomy in resistant neovascular age related macular degeneration.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy